| Views: 117 |
| Date: 11 Jan 2012 |
|
|
|
Definition of medical terminology for Food.
An agent or process effective against a retrovirus.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Infection.
Definition of medical terminology for Patients.
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) recently approved the use of ISENTRESS (raltegravir) in combination with other antiretroviral (ARV) medicines, for the treatment of HIV-1 infection in pediatric patients two years of age and older and weighing at least 10 kg.
Definition of medical terminology for Evaluation.
Definition of medical terminology for Safety.
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
Weight Watchers is a diet plan first developed in the 1960 s
In anatomy, one of the two layers of compact bone
Definition of medical terminology for Syndrome.
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
Definition of medical terminology for Patients.
Definition of medical terminology for Phenylketonuria.
Definition of medical terminology for Safety.
Program Assessment Rating Tool
Definition of medical terminology for HIV-1.
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
FDA Information Retrieval System
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Reverse Transcriptase.
Definition of medical terminology for Protease Inhibitor.
Definition of medical terminology for Patients.
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
Definition of medical terminology for HIV-1.
Definition of medical terminology for Patients.
Definition of medical terminology for Treatment Associated Cancer.
Definition of medical terminology for Patients.
Of or pertaining to a virus.
1. Information gathered at the beginning of a study from which variations found in the study are measured.
Definition of medical terminology for Safety.
Definition of medical terminology for Infection.
The involuntary weight loss of 10% of baseline body weight plus either chronic diarrhea (two loose stools per day for more than 30 days) or chronic weakness and documented fever (for 30 days or more, intermittent or constant) in the absence of a concurrent illness or condition other than HIV infection that would explain the findings.
Definition of medical terminology for Hypersensitivity.
An enzyme that catalyzes the transfer of an amino group from a donor molecule to a recipient molecule.
Definition of medical terminology for Syndrome.
Definition of medical terminology for Evaluation.
Definition of medical terminology for Treatment Associated Cancer.
Definition of medical terminology for Syndrome.
Definition of medical terminology for Insomnia.
Definition of medical terminology for Patients.
Definition of medical terminology for Headache.
Definition of medical terminology for Patients.
Definition of medical terminology for Kinase.
Definition of medical terminology for Laboratory.
Definition of medical terminology for Abnormalities.
Definition of medical terminology for Patients.
Definition of medical terminology for Myopathy.
Definition of medical terminology for Patients.
Definition of medical terminology for Risk.
Definition of medical terminology for Myopathy.
Definition of medical terminology for Patients.
Definition of medical terminology for Integrase.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Infection.
Definition of medical terminology for Patients.
Definition of medical terminology for Patients.
Program Assessment Rating Tool
Definition of medical terminology for Integrase.
Definition of medical terminology for HIV-1.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Integrase.
An agent that kills a virus or that suppresses its ability to replicate and, hence, inhibits its capability to multiply and reproduce.
Definition of medical terminology for Integrase.
Definition of medical terminology for Ability.
A microorganism smaller than a bacteria, which cannot grow or reproduce apart from a living cell.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Drugs.
Definition of medical terminology for Enzymes.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Reverse Transcriptase.
A medication approved for marketing.
Definition of medical terminology for Integrase.
Definition of medical terminology for Enzyme Activation.
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
Definition of medical terminology for Filings.
An agency of the United Nations established in 1948 to further international cooperation in improving health conditions.
Definition of medical terminology for Patients.
Definition of medical terminology for Patient.
Definition of medical terminology for Food.
Definition of medical terminology for Patients.
Definition of medical terminology for Patients.
Definition of medical terminology for HIV-1.
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
Definition of medical terminology for Daily Living Activity.
Weight Watchers is a diet plan first developed in the 1960 s
Definition of medical terminology for Patients.
Definition of medical terminology for Healthcare.
Definition of medical terminology for Well Differentiated Oligodendroglioma.
Definition of medical terminology for Prescription.
Definition of medical terminology for Health.
Definition of medical terminology for Health.
1. In general, a means of approaching something.
Definition of medical terminology for Healthcare.
Definition of medical terminology for Programs.
This new indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of ISENTRESS through at least 24-weeks, in a multicenter, open-label, non-comparative study, in HIV-1-infected children and adolescents two to 18 years of age. The safety and efficacy of ISENTRESS have not been established in children less than two years of age. The FDA also has approved a chewable tablet formulation of ISENTRESS for the treatment of children two to less than 12 years of age. For children ages two to less than 12 years of age, the dosing of ISENTRESS is based on the formulation administered and the patientas age and weight . The chewable table formulation is expected to be available by mid-year of 2012.
Severe potentially life-threatening and fatal skin reactions have been reported with ISENTRESS. Additionally, during the initial phase of treatment, immune reconstitution syndrome may occur. The chewable tablet formulation contains phenylalanine, a component of aspartame, which may be harmful to patients with phenylketonuria. (See Important Selected Safety Information below.)
aISENTRESS is now a new treatment option as part of a regimen for children ages two years and older living with HIV-1 in the U.S.,a said Hedy Teppler, Senior Director, Clinical Research, Merck. aThis advancement underscores Merckas longstanding commitment to help in the fight against HIV, which spans more than 25 years.a ISENTRESS, used in combination with other ARV medicines, was approved by the FDA for use in the treatment of adult patients starting HIV-1 therapy for the first time (treatment-naAve) in 2009, and in treatment-experienced adult patients with HIV-1 in 2007.
IMPAACT P1066 Study Design
This new FDA approval to expand the indication for ISENTRESS to include pediatric patients ages two years and older infected with HIV-1 was based on 24-week results from an ongoing Phase I/II open-label, multicenter trial (IMPAACT P1066) that evaluated the pharmacokinetic profile, safety, tolerability and efficacy of ISENTRESS in HIV-1-infected children and adolescents used with optimized background therapy. The IMPAACT trial enrolled 126 treatment-experienced HIV-1-infected children and adolescents ranging from two to 18 years of age (median age 13 years). Most subjects had previously used at least one non-nucleoside reverse transcriptase inhibitor (78 percent) or one protease inhibitor (83 percent). Ninety-six patients received either the 400 mg film-coated tablet formulation (six to 18 years of age) or the chewable tablet formulation (two to less than 12 years of age) of ISENTRESS, dosed orally twice-daily in combination with optimized background therapy. At baseline, mean plasma HIV-1 RNA was 4.3 log10 copies/mL and the mean CD4 cell count was 481 cells/mm3. Ninety-three patients (97 percent) completed 24 weeks of treatment . At Week 24, 54 percent of patients achieved a viral load of less than 50 copies/mL, and the mean CD4 cell count increase from baseline was 119 cells/mm3 (3.8 percent).
In the IMPAACT 1066 study, the frequency, type and severity of drug-related adverse reactions experienced through Week 24 by these 96 treatment-experienced children and adolescents were comparable to those observed in adults.
Important Selected Safety Information
ISENTRESS does not cure HIV infection or AIDS .
Severe, potentially life-threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis. Immediately discontinue treatment with ISENTRESS and other suspect agents if severe hypersensitivity, severe rash, or rash with systematic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely.
Healthcare providers should know that during the initial phase of treatment, immune reconstitution syndrome can occur, which may necessitate further evaluation and treatment . Monitor for immune reconstitution syndrome.
The most common adverse reactions of moderate to severe intensity greater than or equal to two percent that occurred at a higher rate than the comparator were insomnia (four percent) in treatment-naAve adult patients and headache (2 percent) in treatment-experienced adult patients. Intensities were defined as follows: Moderate (discomfort enough to cause interference with usual activity); or Severe (incapacitating with inability to work or do usual activity).
Grade 2-4 creatine kinase laboratory abnormalities were observed in patients treated with ISENTRESS. Myopathy and rhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions.
Rash occurred more commonly in treatment-experienced subjects receiving regimens containing ISENTRESS + darunavir/ritonavir compared to subjects receiving ISENTRESS without darunavir/ritonavir or darunavir/ritonavir without ISENTRESS. However, rash that was considered drug related occurred at similar rates for all 3 groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash.
About ISENTRESS
ISENTRESS is Merck`s integrase inhibitor for the treatment of HIV-1 infection in adult patients and pediatric patients ages two years and older as part of combination HIV therapy. ISENTRESS is currently the only approved integrase inhibitor for the treatment of HIV-1. ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. Other HIV-1 drugs in use inhibit two other enzymes critical to the HIV-1 replication process a protease and reverse transcriptase a but ISENTRESS is the only approved drug that inhibits the integrase enzyme . ISENTRESS is now approved in combination therapy in more than 45 countries for use in treatment-naAve adult patients with HIV-1 and in more than 90 countries for use in treatment-experienced adult patients with HIV-1. Merck is continuing to move forward with filings in additional countries around the world .
To assist patients taking ISENTRESS, Merck offers the SUPPORTa program, which provides personal support and patient advocacy regarding individual reimbursement issues.
Dosage and Administration
ISENTRESS can be taken with or without food. For the treatment of adult patients and patients 12 years of age and older with HIV-1 infection, the dosage of ISENTRESS is one 400 mg film-coated tablet orally, twice daily . For children ages two to less than 12 years of age, the dosing of ISENTRESS is based on the formulation administered and the patientas age and weight . During co-administration with rifampin, the recommended dosage of ISENTRESS in adults is 800 mg twice-daily. Rifampin a strong inducer of UGT1A1, reduces plasma concentrations of ISENTRESS. Therefore, the dose of ISENTRESS in adults should be increased during co-administration with rifampin. There are no data to guide co-administration of ISENTRESS with rifampin in patients below 18 years of age.
About Merck
Today`s Merck is a global healthcare leader working to help the world be well . Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Source :
DrugsFreeList.com
Tags:
raltegravir, Isentress, antiretroviral medicines
|
